FDA Panel Narrowly Backs Ofev Label Expansion |
News and Updates
eMediNexus Coverage from: 
FDA Panel Narrowly Backs Ofev Label Expansion
eMediNexus,  27 July 2019
remove_red_eye 518 Views
#Internal Medicine #Pharmacist #Pulmonary Medicine

0 Read Comments                

An FDA advisory committee voted 10-7 that nintedanib (Ofev) should be approved to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Currently marketed to treat idiopathic pulmonary fibrosis (IPF), nintedanib would become the first drug approved for SSc-ILD, a condition with few other options for treatment.

The main data supporting the label expansion came from the phase III, double-blind, placebo-controlled SENSCIS trial involving some 580 patients across 32 countries… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now